Inventor · disambiguated record
Paul J. Hergenrother
Also filed as: HERGENROTHER PAUL · HERGENROTHER PAUL J · HERGENROTHER PAUL JOSEPH
59 granted patents·21 pending applications·231 citations·filing 2002–2024
98Inventor score
Files withUNIV ILLINOIS61HERGENROTHER PAUL J7MASSACHUSETTS INST TECHNOLOGY6UNIV TEXAS3HERGENROTHER PAUL JOSEPH1
Top patents by PatentIndex Score
80 records- 0195US9663482B2Substituted piperazinyl acetohydrazide procaspase-activating compoundsUNIV ILLINOIS·Filed 2016·Granted May 30, 2017·8 cites·18 claims
- 0295US8916705B2Procaspase-activating compounds and compositionsUNIV ILLINOIS·Filed 2012·Granted Dec 23, 2014·12 cites·8 claims
- 0394US9962383B2Compounds, compositions and methods of agelastatin alkaloidsMASSACHUSETTS INST TECHNOLOGY·Filed 2016·Granted May 8, 2018·7 cites·27 claims
- 0493US11129830B2PAC-1 combination therapyUNIV ILLINOIS·Filed 2019·Granted Sep 28, 2021·6 cites·18 claims
- 0593US9249116B2Enzyme-activating compounds and compositionsUNIV ILLINOIS·Filed 2013·Granted Feb 2, 2016·10 cites·19 claims
- 0692US12168006B2Cancer therapy by degrading dual MEK signalingUNIV ILLINOIS·Filed 2022·Granted Dec 17, 2024·1 cites·13 claims
- 0792US8592584B2Compositions and methods including cell death inducers and procaspase activationHERGENROTHER PAUL J·Filed 2011·Granted Nov 26, 2013·21 cites·1 claims
- 0891US9353150B2Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatmentMASSACHUSETTS INST TECHNOLOGY·Filed 2013·Granted May 31, 2016·10 cites·11 claims
- 0990US11046647B2Activators of the unfolded protein responseUNIV ILLINOIS·Filed 2020·Granted Jun 29, 2021·2 cites·11 claims
- 1090US9522901B2Compositions and methods including cell death inducers and procaspase activationUNIV ILLINOIS·Filed 2013·Granted Dec 20, 2016·6 cites·20 claims
- 1190US8754084B2Therapeutic methods and agents for treating myotonic dystrophyUNIV ILLINOIS·Filed 2013·Granted Jun 17, 2014·10 cites·20 claims
- 1289US10350207B2PAC-1 combination therapyUNIV ILLINOIS·Filed 2016·Granted Jul 16, 2019·4 cites·4 claims
- 1389US10220099B2Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatmentMASSACHUSETTS INST TECHNOLOGY·Filed 2016·Granted Mar 5, 2019·6 cites·24 claims
- 1489US9102661B2Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugsUNIV ILLINOIS·Filed 2014·Granted Aug 11, 2015·15 cites·27 claims
- 1588US9434736B2Compounds, compositions and methods of agelastatin alkaloidsMASSACHUSETTS INST TECHNOLOGY·Filed 2014·Granted Sep 6, 2016·9 cites·20 claims
- 1687US10918735B2Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatmentMASSACHUSETTS INST TECHNOLOGY·Filed 2019·Granted Feb 16, 2021·3 cites·29 claims
- 1787US9382215B2Therapeutic methods and agents for treating myotonic dystrophyUNIV ILLINOIS·Filed 2014·Granted Jul 5, 2016·6 cites·18 claims
- 1886US12433885B2Procaspase combination therapy for glioblastomaUNIV ILLINOIS·Filed 2023·Granted Oct 7, 2025·0 cites·16 claims
- 1986US11510919B2Cancer therapy by degrading dual MEK signalingUNIV ILLINOIS·Filed 2018·Granted Nov 29, 2022·5 cites·19 claims
- 2086US9643960B2Procaspase activating compoundsUNIV ILLINOIS·Filed 2015·Granted May 9, 2017·7 cites·21 claims
- 2186US9421202B2Procaspase combination therapy for glioblastomaHERGENROTHER PAUL J·Filed 2013·Granted Aug 23, 2016·9 cites·20 claims
- 2286US9399035B2Procaspase 3 activation by combination therapyHERGENROTHER PAUL J·Filed 2013·Granted Jul 26, 2016·8 cites·5 claims
- 2385US8778945B2Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugsHERGENROTHER PAUL JOSEPH·Filed 2010·Granted Jul 15, 2014·17 cites·16 claims
- 2485US7632972B2Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cellsUNIV ALABAMA·Filed 2004·Granted Dec 15, 2009·25 cites·34 claims
- 2584US10888560B2Procaspase 3 activation by combination therapyUNIV ILLINOIS·Filed 2018·Granted Jan 12, 2021·1 cites·10 claims
- 2684US9592229B2Potent anticancer activity via dual compound activationUNIV ILLINOIS·Filed 2013·Granted Mar 14, 2017·8 cites·21 claims
- 2783US12090153B2Combination therapy for the treatment of uveal melanomaUNIV ILLINOIS·Filed 2019·Granted Sep 17, 2024·1 cites·21 claims
- 2882US11274106B2Topoisomerase inhibitors with antibacterial and anticancer activityUNIV ILLINOIS·Filed 2018·Granted Mar 15, 2022·2 cites·13 claims
- 2982US9611266B2Compounds and anti-tumor NQO1 substratesUNIV ILLINOIS·Filed 2016·Granted Apr 4, 2017·3 cites·20 claims
- 3079US10995097B2Small molecules active against gram-negative bacteriaUNIV ILLINOIS·Filed 2017·Granted May 4, 2021·3 cites·15 claims
- 3177US10874666B2Procaspase combination therapy for glioblastomaUNIV ILLINOIS·Filed 2018·Granted Dec 29, 2020·1 cites·12 claims
- 3275US10085978B2Procaspase combination therapy for glioblastomaUNIV ILLINOIS·Filed 2016·Granted Oct 2, 2018·1 cites·10 claims
- 3374US11844798B2Procaspase combination therapy for glioblastomaUNIV ILLINOIS·Filed 2020·Granted Dec 19, 2023·0 cites·6 claims
- 3474US11833147B2Procaspase 3 activation by combination therapyUNIV ILLINOIS·Filed 2021·Granted Dec 5, 2023·0 cites·6 claims
- 3574US10085977B2Procaspase 3 activation by combination therapyUNIV ILLINOIS·Filed 2016·Granted Oct 2, 2018·1 cites·18 claims
- 3673US12336992B2PAC-1 combination therapyUNIV ILLINOIS·Filed 2021·Granted Jun 24, 2025·0 cites·17 claims
- 3772US12180159B2Activators of the unfolded protein responseUNIV ILLINOIS·Filed 2019·Granted Dec 31, 2024·0 cites·24 claims
- 3872US11584718B2Activators of the unfolded protein responseUNIV ILLINOIS·Filed 2021·Granted Feb 21, 2023·0 cites·20 claims
- 3972US2025270197A1Ribocil c antibiotics effective for gram-negative pathogensUNIV ILLINOIS·Filed 2024·Application pending·0 cites
- 4071US12234240B2Substituted imidazo[5,1-d][1,2,3,5]tetrazines for the treatment of cancerUNIV ILLINOIS·Filed 2022·Granted Feb 25, 2025·0 cites·13 claims
- 4171US10525056B2Procaspase-activating compounds and methodsUNIV ILLINOIS·Filed 2018·Granted Jan 7, 2020·0 cites·16 claims
- 4270US10272099B2Tumor-selective combination therapyUNIV TEXAS·Filed 2014·Granted Apr 30, 2019·2 cites·20 claims
- 4369US12180198B2Ribocil C antibiotics effective for Gram-negative pathogensUNIV ILLINOIS·Filed 2023·Granted Dec 31, 2024·0 cites·20 claims
- 4469US10022371B2Procaspase-activating compounds and methodsUNIV ILLINOIS·Filed 2014·Granted Jul 17, 2018·0 cites·17 claims
- 4569US9233960B2Compounds and anti-tumor NQO1 substratesHERGENROTHER PAUL J·Filed 2012·Granted Jan 12, 2016·1 cites·20 claims
- 4667US11612598B2Compounds and methods for the treatment of cancerUNIV ILLINOIS·Filed 2018·Granted Mar 28, 2023·0 cites·6 claims
- 4766US10166229B2Compounds and methods for the treatment of cancerUNIV ILLINOIS·Filed 2016·Granted Jan 1, 2019·0 cites·23 claims
- 4864US2018360830A1Compounds, compositions and methods of agelastatin alkaloidsMASSACHUSETTS INST TECHNOLOGY·Filed 2018·Application pending·0 cites
- 4964US2021315886A1Imidazotetrazine compoundsUNIV ILLINOIS·Filed 2019·Application pending·0 cites
- 5063US2024400606A1Small molecule activators of the immune systemUNIV ILLINOIS·Filed 2022·Application pending·0 cites
Showing the top 50 of 80 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Paul J. Hergenrother files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →